Stockreport

ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF Application based on results from DESTINY-PanTumor02 trial and supported by additional ENHERTU dataSubmission to be reviewed under FDA Real Time Oncology Review and Proj [Read more]